Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132202 | 0.86 | ALDH1A1 (0.59) | PYCR1RAB9ANPC1HPGDCA12 | |
| SCHEMBL31411911 | 0.84 | NCEH1 (0.46) | PYCR1RAB9ANPC1HPGDCA12 | |
| SCHEMBL3236512 | 0.83 | RAB9A (0.50) | RAB9ANPC1HPGDCA12CA9 | |
| SCHEMBL26087008 | 0.83 | ALDH1A1 (0.56) | RAB9ANPC1HPGDCA12CA9 | |
| SCHEMBL11209189 | 0.81 | RAB9A (0.52) | RAB9ANPC1HPGDCA12CA9 | |
| SCHEMBL1935803 | 0.81 | RAB9A (0.52) | RAB9ANPC1HPGDCA12CA9 | |
| SCHEMBL180384 | 0.80 | NPC1 (0.73) | RAB9ANPC1HPGDCA12CA9 | |
| SCHEMBL2634610 | 0.80 | RIPK1 (0.64) | PYCR1RAB9ANPC1HPGDCA12 | |
| SCHEMBL23275292 | 0.79 | RAB9A (0.50) | PYCR1RAB9ANPC1HPGDCA12 | |
| SCHEMBL4806015 | 0.79 | RAB9A (0.50) | RAB9ANPC1HPGDCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| CN-111205310-A | Heterocyclic fused pyrimidine derivative, and pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20180265484-A1 | HEPATITIS B CORE PROTEIN MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-09-20 | — | — | US | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2496558-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | PYCR1 1415/4885RAB9A 3155/4885NPC1 4305/4885 |
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | PYCR1 1388/4885RAB9A 2560/4885NPC1 2432/4885 |
| US-20180265484-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | PYCR1 4407/4885RAB9A 1073/4885NPC1 447/4885 |
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | PYCR1 30/4885RAB9A 4085/4885NPC1 3941/4885 |
| US-10766890-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | PYCR1 4407/4885RAB9A 1073/4885NPC1 447/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | PYCR1 1388/4885RAB9A 2560/4885NPC1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.